Stockreport

MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019

MYOKARDIA  (MYOK) 
Last myokardia earnings: 2/27 04:05 pm Check Earnings Report
PDF Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Signif [Read more]